Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for multiplexed drug evaluation

Inactive Publication Date: 2014-06-19
PRESAGE BIOSCI
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a method for evaluating agents in solid tissue by delivering them through needles and measuring their effectiveness using mass spectrometry. The method can deliver two or more agents to different sites in the tissue and evaluate their efficacy. The agents can be delivered simultaneously or sequentially. The method can also remove the tissue or the site where the agents are delivered. The mass spectrometry can be imaging or tandem MS / MS. The method can be used with various types of agents such as chemotherapy agents, small molecule agents, anti-cancer agents, gene therapy agents, and biologics. The method can also be used with agents in clinical trials. The technical effect of the patent is to provide a reliable and effective method for evaluating agents in solid tissue.

Problems solved by technology

Numerous cancer-related therapeutics are under preclinical, phase I or phase II clinical trial and evaluations at any particular time; however, most of them will fail to advance.
In fact, numerous drug candidates fail in the preclinical test, and it is estimated that more than 90% of cancer-related therapeutics will fail phase I or II clinical trial evaluation.
The failure rate in phase III trials is almost 50%, and the cost of new drug development from discovery through phase III trials is between $0.8 billion and $1.7 billion and can take between eight and ten years.
In addition, many subjects fail to respond even to standard drugs that have been shown to be efficacious.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for multiplexed drug evaluation
  • Methods for multiplexed drug evaluation
  • Methods for multiplexed drug evaluation

Examples

Experimental program
Comparison scheme
Effect test

example 1

Evaluation of Agents with Mass Spectrometry

[0243]In some embodiments of the methods of the disclosure, an agent is loaded into an injection device. The agents loaded into the injection device comprise an anti-cancer agent and a control agent. The agents are injected into the solid tissue, resulting in a plurality of delivery sites. The delivery sites comprise the agents, wherein one delivery site comprises a first agent; a second delivery site comprises a second agent, etc.

[0244]After 24 hours, the solid tissue is imaged. The injection sites are removed and lysed. The lysis is desalted. The lysis is mixed with a matrix and spotted on a MALDI-TOF analysis plate. The spots are dried and then subjected to imaging mass spectrometry.

[0245]The mass spectrometry data is compiled and overlayed on the image of the tumor. In some instances, the mass spectrometry data indicates the abundance, distribution and / or presence or absence of an agent and / or a biomarker. In some instances, the agent a...

example 2

Categorization of Subjects by Evaluation of Solid Tissues with Mass Spectrometry

[0246]In some embodiments of the methods of the disclosure, an agent is loaded into an injection device. The agents loaded into the injection device comprise an anti-cancer agent and a control agent. The agents are injected into the solid tissue, resulting in a plurality of delivery sites. The delivery sites comprise the agents, wherein one delivery site comprises a first agent, a second delivery site comprises a second agent, etc.

[0247]After 24 hours, the solid tissue is imaged. The injection sites are removed and lysed. The lysis is desalted. The lysis is mixed with a matrix and spotted on a MALDI-TOF analysis plate. The spots are dried and then subjected to imaging mass spectrometry.

[0248]The mass spectrometry data is compiled and the solid tissue is evaluated for response to the agent. In some instances, the solid tissue is found to be unresponsive to the agent. The solid tissue and / or the subject fr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Concentrationaaaaaaaaaa
Areaaaaaaaaaaa
Login to View More

Abstract

Methods for multiplexed delivery of agents to a solid tissue in vivo followed by assessment of efficacy with mass spectrometry are described.

Description

CROSS-REFERENCE[0001]This application claims the benefit of U.S. Provisional Application No. 61 / 725,978, filed Nov. 13, 2012, which application is incorporated herein by reference.BACKGROUND[0002]Numerous cancer-related therapeutics are under preclinical, phase I or phase II clinical trial and evaluations at any particular time; however, most of them will fail to advance. In fact, numerous drug candidates fail in the preclinical test, and it is estimated that more than 90% of cancer-related therapeutics will fail phase I or II clinical trial evaluation. The failure rate in phase III trials is almost 50%, and the cost of new drug development from discovery through phase III trials is between $0.8 billion and $1.7 billion and can take between eight and ten years.[0003]In addition, many subjects fail to respond even to standard drugs that have been shown to be efficacious. Excessive systemic concentrations can be maintained for many oncology drug candidates in efforts to achieve a desi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/50G01N33/15
CPCG01N33/5011G01N33/5088G01N33/6848G01N2500/00G16C20/90G01N33/15
Inventor KLINGHOFFER, RICHARDCAFFO, NATHAN
Owner PRESAGE BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com